BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol 2021. [PMID: 34472091 DOI: 10.1111/bjh.17805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 A. Al-anazi K. Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies. Recent Update on Multiple Myeloma [Working Title] 2023. [DOI: 10.5772/intechopen.109279] [Reference Citation Analysis]
2 Hasselbalch H, Skov V, Kjær L, Larsen MK, Knudsen TA, Lucijanić M, Kusec R. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers (Basel) 2022;14. [PMID: 36428587 DOI: 10.3390/cancers14225495] [Reference Citation Analysis]
3 Costa BA, Mouhieddine TH, Richter J. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Target Oncol 2022. [PMID: 35771402 DOI: 10.1007/s11523-022-00897-8] [Reference Citation Analysis]
4 Derudas D, Concu C. Management of Renal Failure in Multiple Myeloma. Recent Update on Multiple Myeloma [Working Title] 2022. [DOI: 10.5772/intechopen.105444] [Reference Citation Analysis]
5 Watson E, Djebbari F, Rampotas A, Ramasamy K. BCMA-targeted therapies for multiple myeloma: strategies to maximise efficacy and minimize adverse events. Expert Rev Hematol 2022. [PMID: 35633050 DOI: 10.1080/17474086.2022.2084068] [Reference Citation Analysis]
6 Chng WJ. New immunotherapeutic target in myeloma. Blood 2022;139:2417-8. [PMID: 35446380 DOI: 10.1182/blood.2022015481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tai W, Wahab A, Franco D, Shah Z, Ashraf A, Abid Q, Mohammed YN, Lal D, Anwer F. Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma. Antibodies 2022;11:22. [DOI: 10.3390/antib11020022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Pozzi S, Bari A, Pecherstorfer M, Vallet S. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers (Basel) 2021;13:4978. [PMID: 34638462 DOI: 10.3390/cancers13194978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]